Spark Therapeutics, Inc. (NASDAQ:ONCE) CEO Jeffrey D. Marrazzo sold 20,000 shares of the company’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the completion of the sale, the chief executive officer now directly owns 250,000 shares of the company’s stock, valued at $17,885,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) traded up $0.49 on Monday, reaching $72.25. 372,800 shares of the company’s stock traded hands, compared to its average volume of 488,067. Spark Therapeutics, Inc. has a one year low of $47.03 and a one year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million for the quarter, compared to analyst estimates of $1.40 million. During the same quarter in the previous year, the company posted ($1.07) earnings per share. The company’s quarterly revenue was up 45.8% compared to the same quarter last year. equities analysts anticipate that Spark Therapeutics, Inc. will post -7.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/spark-therapeutics-inc-once-ceo-sells-1430800-00-in-stock/1700970.html.

A number of institutional investors and hedge funds have recently modified their holdings of ONCE. Principal Financial Group Inc. grew its position in Spark Therapeutics by 0.3% during the first quarter. Principal Financial Group Inc. now owns 38,752 shares of the biotechnology company’s stock worth $2,067,000 after buying an additional 122 shares during the period. Teachers Advisors LLC grew its position in Spark Therapeutics by 1.9% during the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock worth $1,842,000 after buying an additional 650 shares during the period. Vanguard Group Inc. grew its position in Spark Therapeutics by 5.2% during the first quarter. Vanguard Group Inc. now owns 1,827,660 shares of the biotechnology company’s stock worth $97,487,000 after buying an additional 90,686 shares during the period. Geode Capital Management LLC grew its position in Spark Therapeutics by 4.9% during the first quarter. Geode Capital Management LLC now owns 177,154 shares of the biotechnology company’s stock worth $9,449,000 after buying an additional 8,284 shares during the period. Finally, BlackRock Inc. grew its position in Spark Therapeutics by 11,332.0% during the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock worth $98,158,000 after buying an additional 1,824,117 shares during the period. Institutional investors own 77.94% of the company’s stock.

A number of brokerages have recently commented on ONCE. Royal Bank Of Canada reduced their target price on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a report on Wednesday, November 8th. SunTrust Banks, Inc. set a $101.00 target price on shares of Spark Therapeutics and gave the company a “buy” rating in a report on Monday, October 16th. Barclays PLC upped their target price on shares of Spark Therapeutics from $104.00 to $107.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Cantor Fitzgerald cut their price target on shares of Spark Therapeutics from $105.00 to $94.00 and set a “buy” rating for the company in a report on Friday, October 13th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $101.00 price target (up from $92.00) on shares of Spark Therapeutics in a report on Friday, October 13th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and eighteen have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $90.36.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.